{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-DM1&page=2",
    "query": {
      "intervention": "T-DM1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-DM1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T12:37:50.715Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02390427",
      "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otto Metzger, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2015-04-20",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02390427"
    },
    {
      "nct_id": "NCT05650879",
      "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Mutant Non-small Cell Lung Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Gene Mutation",
        "HER2 Amplification"
      ],
      "interventions": [
        {
          "name": "ELVN-002",
          "type": "DRUG"
        },
        {
          "name": "Fam-Trastuzumab Deruxtecan-Nxki",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enliven Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2023-03-20",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05650879"
    },
    {
      "nct_id": "NCT01976169",
      "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PD-0332991 and T-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 29,
      "start_date": "2014-01-24",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01976169"
    },
    {
      "nct_id": "NCT01772472",
      "title": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab emtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1486,
      "start_date": "2013-04-03",
      "completion_date": "2024-05-23",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 60,
      "location_summary": "Anchorage, Alaska • Long Beach, California • Orange, California + 49 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772472"
    },
    {
      "nct_id": "NCT00991562",
      "title": "IMGN901 in Combination With Lenalidomide and Dexamethasone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "IMGN901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-12",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-11-21",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palm Springs, California • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991562"
    },
    {
      "nct_id": "NCT01120561",
      "title": "A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab-MCC-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2010-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 15,
      "location_summary": "Highland, California • Stockton, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Highland",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120561"
    },
    {
      "nct_id": "NCT03587740",
      "title": "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "T-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2018-08-22",
      "completion_date": "2027-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Brighton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587740"
    },
    {
      "nct_id": "NCT04632992",
      "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Unresectable or Metastatic Solid Malignancy"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Investigator's Choice of Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Pralsetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2021-01-13",
      "completion_date": "2024-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 38,
      "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Oro Valley",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632992"
    },
    {
      "nct_id": "NCT03190967",
      "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Metastasis",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "T-DM1",
          "type": "DRUG"
        },
        {
          "name": "TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-04-18",
      "completion_date": "2023-06-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190967"
    },
    {
      "nct_id": "NCT04197687",
      "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Multi-epitope HER2 Peptide Vaccine TPIV100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 480,
      "start_date": "2020-02-20",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-09-14T12:37:50.715Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197687"
    }
  ]
}